首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1856017

止痛藥市場：化挑戰為機會－掌握自我照護止痛市場的機會

Analgesics From Pain to Gain - Unlocking Opportunities in the Self-Care Analgesics Market

出版日期: 2025年11月06日 | 出版商:

Nicholas Hall Group of Companies | 英文 346 Pages | 訂單完成後即時交付

價格

簡介目錄

過去幾年，全球止痛藥市場保持穩定成長，但隨著後疫情時代消費模式的恢復，成長速度有所放緩。全身用藥正朝著起效更快、更方便的方向發展，複方製劑和新興趨勢正在某些市場擴大該品類。感冒和流感的盛行率在不同市場差異顯著，兒童止痛藥在低流行地區受到的衝擊尤為嚴重。外用止痛藥則受益於人們積極參與運動的增加、老年人口的增長以及緩解經期不適的新產品。

網路和郵購銷售的成長速度持續超過實體店銷售，線上通路的佔有率不斷擴大，一些熱門止痛藥產品也呈現顯著成長。為了打造差異化品牌，A+P 正著眼於各年齡層的消費者，結合多種促銷策略和媒體管道，並日益強調包容性和社會責任。

不同市場的新產品開發重點各不相同。近期推出的產品包括：澳洲全球首款塞來昔布轉換劑型、德國首款右旋布洛芬，以及一家大型感冒咳嗽藥品牌進軍美國全身及局部止痛藥市場。創新劑型層出不窮，例如容易吞嚥的迷你膠囊、鼻噴劑、依摩球和筆狀塗抹器。針對不同人群（包括青少年、上班族、運動愛好者和匹克球運動員）的區隔產品正在拓展該品類。同時，成熟的止痛藥品牌也越來越多地進軍關節保健品領域。

市場動態的銷售預測與歷史成長基本上一致，但在這個成熟的市場中，行銷人員如何找到新的活力？他們如何利用近期趨勢和發展，或拓展產品線以開闢新的區隔市場？

本報告探討了影響全球止痛藥物市場的緊迫問題，深入分析了多個相關領域，並重點介紹了獨特的機會。透過詳細檢視12個主要市場（並簡要介紹其他主要市場），分析品牌表現和上市活動，我們的 "止痛" 報告挖掘了這個保健保健品類別的巨大潛力。

報告主要特點

對止痛市場進行詳區隔析，包括全身用藥、外用藥和口腔/牙科止痛藥。
檢視全球16個主要市場，涵蓋銷售、品牌表現、最新進展、產品上市及促銷活動。
同時檢視關節保健品，這是一個重要的維生素、礦物質和膳食補充劑（VMS）相關類別。
我們專門的CHC銷售資料庫，包含6個獨立的資料庫。除了截至2024年底的最新銷售數據外，本報告還提供截至2020年的歷史成長率以及截至2025年中期的各類別銷售額成長率。每個國家的品類銷售額均依組成部分區隔。報告中還包含各市場的互聯網和郵購銷售額。全面涵蓋行銷活動，包括策略、成功因素、銷售、新產品開發活動以及面向消費者和醫療保健專業人員的促銷活動。
所有類別和國家的長期預測（至 2029 年和 2034 年），以及更新的短期預測（至 2025 年和 2026 年）

本報告涵蓋的類別

全身止痛藥
局部止痛藥

口腔和牙科鎮痛藥
關節補充劑
*

*VMSinDB6 中追蹤的銷售量。

12個獨立市場的詳區隔析

澳大利亞
巴西
中國
法國
德國
印度

義大利
日本
墨西哥
波蘭
英國
美國

其他市場

加拿大
俄羅斯

韓國
西班牙

本報告包含截至2024年底的DB6資料庫最新銷售數據。報告提供依國家和類別劃分的全球銷售額、各品牌表現以及至2029年和2034年的長期預測。報告也涵蓋線上管道，並設有專門章節介紹止痛藥線上銷售及各國概況。

本報告深入分析影響各個鎮痛藥市場的因素，涵蓋消費者趨勢、監管變化、廣告宣傳活動和新產品上市等，並詳細闡述了12個國家的市場趨勢和發展動態，以及其他主要市場的更詳細概況，包括洞察分析和預測。

本報告探討的關鍵問題

可以從最成功的止痛藥行銷商和品牌中學到什麼？
新產品開發是否有利於市場並為其成長指明方向？
考慮競爭格局、消費者偏好、電子商務環境和未來推動因素，哪些市場最具發展潛力？
能否發現新的利基市場或服務不足的市場區隔？
關節保健品這一相鄰品類是否值得探索？
止痛藥的前景和商機是什麼？

在國別數據分析中，依主要成分分析了2024年全身和外用止痛藥的銷售數據。

我們也探討了一個重要的鄰近類別－關節保健品，NPD認為該類別正在推動整個品類的擴張。

對於短期展望，我們提供了各市場所有品類2025年和2026年的預測。

隨著止痛藥上市速度逐年放緩，市場需要從追求數量轉向追求品質。

Analgesics globally have sustained steady growth in recent years, albeit slowing as purchasing patterns returned to normal post-Covid. Systemics show a trend towards faster-acting, more convenient options, while combinations and new switches expand the category in selected markets. Incidence of cold & flu, which varies considerably between markets, has been a strong influence, with paediatric fever relievers particularly hard hit in areas of low incidence. Topicals benefit from rising participation in active pursuits, a growing elderly population and new products to relieve menstrual discomfort.

Internet & mail order sales continue to grow more dynamically than store retail, seeing the channel account for a growing share, as several top-tier analgesics enjoy standout online channel growth. In an effort to differentiate brands, A+P has targeted both ends of the age spectrum, with a mix of promotional strategies and media employed, with inclusivity and social responsibility increasingly to the fore.

NPD focus varies across markets. Recent launch activity has seen the world-first switch of celecoxib in Australia, Germany's first dexibuprofen launch and the main cough & cold franchise enter both systemic and topical analgesics in USA. Format innovation includes easy-to-swallow and mini-capsule options, plus nasal sprays, massage balls and pen applicators, while niche products for demographics as diverse as teenagers, office workers, sports enthusiasts and even pickleball players are expanding the category. Meanwhile, established analgesics brands are increasingly crossing into joint health supplements.

Forecast sales for Analgesics are largely consistent with previous growth, so where can marketers look to find dynamism in this mature market? How will they take advantage of the latest trends & developments or expand their offerings to exploit new niches?

This report will investigate pressing issues affecting Analgesics globally, digging into multiple areas of interest and highlighting inherent opportunities. Examining 12 core markets in detail (and additional key markets in brief), analysing brand performances and launch activity, our Analgesics report will investigate the untapped potential in this CHC category.

Key features of the report:

An in-depth exploration of the pain relief market, including Systemic analgesics, Topical analgesics and Mouth & dental analgesics
Coverage of 16 major markets from across the globe, with topline sales,brand performances, latest developments, launches and promotional campaigns
Key VMS adjacency joint health supplements also investigated
Very latest year-end 2024 sales from DB6, our dedicated CHC sales database, plus historical growth rates back to 2020 and mid-2025 topline growth across categories
Category sales segmented by ingredient in each country
Internet & mail order channel sales for every market profiled
Coverage of marketer activity, highlighting strategies and success factors, sales, NPD activity and consumer & HCP promotion
A look to the future includes long-term forecast sales for all categories and countries to 2029 & 2034, plus the most up-to-date short-term forecasts (to 2025 & 2026)

Categories covered in this report include:

Systemic analgesics
Topical analgesics

Mouth & dental analgesics
Joint health supplements *

* sales tracked under VMS in DB6.

12 individual markets profiled in depth:

Australia
Brazil
China
France
Germany
India

Italy
Japan
Mexico
Poland
UK
USA

Plus additional markets in brief:

Canada
Russia

S Korea
Spain

The report features the latest end-2024 sales data from our dedicated DB6 database, including topline historical sales globally , by country and category, as well as individual brand performances, and long-term forecasts to 2029 and 2034 . Coverage extends to the online channel, with internet & mail order sales of Analgesics included in the topline and a dedicated section in each country profile.

Diving into the factors affecting individual Analgesics markets, from consumer trends and regulatory changes to A+P campaigns and new product launch activity, this report sheds light on trends & developments across 12 in-depth country profiles with insights and predictions, as well as shorter profiles of other key markets .

Key questions investigated in this report:

What can be learned from the most successful analgesics marketers & brands?
Has NPD benefited the market and does it offer a route to growth?
Which markets show the most promise based on competitive landscape, consumer preferences, e-commerce environment and future drivers?
Can new niches and underserved demographics be identified?
Does the adjacent category of joint health supplements merit exploring?
What is the outlook for Analgesics and where can opportunities be found?

Data analysis within each country profile includes a breakdown of 2024 sales by key ingredient in Systemic analgesics and Topical analgesics.

The important adjacent category of joint health supplements, where NPD has helped drive category expansion, is also investigated.

Assessing the short-term outlook, the report includes full-year 2025 & 2026 forecasts for all categories in each market profiled.

With launch activity in Analgesics slowing year on year, has the impetus shifted from quantity to quality? New product development is explored across markets, including Rx-to-OTC switches, delivery format innovations, new benefits and more.